- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04669899
Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors
Phase 1/2 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumor Malignancies
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Nancy Mota
- Phone Number: (857) 259-3840
- Email: nmota@jouncetx.com
Study Contact Backup
- Name: Keith Barnett
- Phone Number: (857) 999-2968
- Email: kbarnett@jouncetx.com
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35249
- University of Alabama at Birmingham
-
-
Arizona
-
Gilbert, Arizona, United States, 85234
- Banner MD Anderson Cancer Center
-
Tucson, Arizona, United States, 85258
- Arizona Clinical Research Center
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- University of Arkansas Medical Sciences
-
-
California
-
Duarte, California, United States, 91010
- City of Hope
-
La Jolla, California, United States, 92093
- University of California, San Diego
-
La Jolla, California, United States, 92037
- California Cancer Associates for Research & Excellence, Inc.
-
Los Angeles, California, United States, 90048
- Cedars Sinai
-
Orange, California, United States, 92868
- UC Irvine Medical Center
-
Sacramento, California, United States, 95817
- University of California, Davis
-
-
Connecticut
-
New Haven, Connecticut, United States, 06519
- Yale University
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20057
- Georgetown University
-
-
Florida
-
Gainesville, Florida, United States, 32610
- University of Florida
-
Miami, Florida, United States, 33136
- University of Miami - Sylvester Comprehensive Cancer Center
-
Orlando, Florida, United States, 32803
- Adventist Health System/Sunbelt, Inc.
-
Tampa, Florida, United States, 33606
- Tampa General Hospital
-
-
Georgia
-
Augusta, Georgia, United States, 30909
- Augusta Oncology Associates - Wheeler Road
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago
-
Decatur, Illinois, United States, 62526
- Cancer Care Center of Decatur
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- University of Kentucky Chandler Medical Center (UKCMC)
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Hospital
-
Detroit, Michigan, United States, 48201
- Barbara Ann Karmanos Cancer Center
-
Grand Rapids, Michigan, United States, 49546
- START Midwest -Cancer & Hematology Center of Western Michigan
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Regents of the University of Minnesota
-
-
New York
-
New York, New York, United States, 10029
- Mount Sinai
-
New York, New York, United States, 10021
- Weill Cornell
-
New York, New York, United States, 10461
- Montefiore Medical Center Prime
-
-
North Carolina
-
Huntersville, North Carolina, United States, 28708
- Carolina BioOncology
-
-
Ohio
-
Canton, Ohio, United States, 44718
- Gabrail Cancer Center
-
Cincinnati, Ohio, United States, 45229
- UC Health, LLC
-
Cleveland, Ohio, United States, 44106
- Case Comprehensive Cancer Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Providence Portland Cancer Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- Fox Chase Cancer Center
-
-
South Carolina
-
Greenville, South Carolina, United States, 29605
- Prisma Health
-
-
Texas
-
Dallas, Texas, United States, 75230
- Mary Crowley Cancer Research
-
Houston, Texas, United States, 77030
- MD Anderson
-
Houston, Texas, United States, 77024
- Oncology Consultants, P.A.
-
Lubbock, Texas, United States, 79410
- Joe Arrington Cancer Research & Treatment Center
-
San Antonio, Texas, United States, 78229
- START Texas Accelerated Research Therapeutics
-
-
Utah
-
West Valley City, Utah, United States, 84119
- START Mountain Region
-
-
Washington
-
Seattle, Washington, United States, 98331
- Seattle Cancer Care Alliance
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- The Board of Regents of the University of Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Able and willing to participate and comply with all study requirements and provide signed and dated informed consent prior to initiation of any study procedures;
Histologically or cytologically confirmed advanced/metastatic extracranial solid tumor malignancy:
- Stages 1 and 2: Subjects must have received, have been intolerant to, have been ineligible for, or have declined all treatment known to confer clinical benefit with the exception of subjects enrolled in combination cohorts with a PD-1i, where a PD-1i is approved by the local regulatory agencies;
- Stage 3: This stage may enroll subjects with 3L/4L PD-(L)1-naïve, platinum-resistant ovarian cancer;
Stage 4: This stage may enroll subjects with the following cancers:
- 2L/3L ccRCC. Subjects must have progressed on or after treatment with an anti-PD-(L)1 agent in their most recent prior line of therapy;
- 2L-4L TNBC. Subjects must have progressed on or after treatment with a prior anti-PD-(L)1 therapy;
- 1L, PD-(L)1-naïve, PD-L1+; combined positive score (CPS) ≥1% HNSCC;
- 2L/3L platinum-experienced HNSCC. Subjects must have progressed on or after treatment with an anti-PD-(L)1-agent in their most recent prior line of therapy;
- 3L/4L, PD-(L)1-naïve, platinum-resistant ovarian cancer;
- 2L/3L NSCLC. Subjects must have progressed on or after treatment with platinum-based chemotherapy and an anti-PD-(L)1-containing therapy. The anti-PD-(L)1 agent must have been a part of the most recent prior line of therapy. Subjects with EGFR mutations and ALK rearrangements will be excluded. Subjects with other targetable genomic aberrations for which FDA approved therapies exist must have received appropriate FDA-approved targeted therapy;
- 2L/3L cSCC. Subjects must have progressed on or after treatment with an anti-PD-(L)1 agent in their most recent prior line of therapy;
- 2L-4L PD-(L)1-naïve undifferentiated pleomorphic sarcoma (UPS) and liposarcoma (LPS);
- 2L/3L biliary tract cancer (BTC), including intra- and extra-hepatic biliary duct cancer and cancer of the gallbladder. Subjects must have progressed on or after gemcitabine/cisplatin (Gem/Cis) in the metastatic setting and must have PD-(L)1 inhibitor resistance. Subjects with FGFR and IDH1 mutations must have progressed on or after targeted therapies for these mutations;
- Measurable disease, according to the RECIST version 1.1, that has objectively progressed since (or on) previous treatment as assessed by the Investigator;
- ≥18 years of age;
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;
- Predicted life expectancy of ≥3 months;
- Have specified laboratory values (obtained ≤28 days prior to planned Cycle 1, Day 1 [C1D1]) in accordance with the study protocol;
- For women of childbearing potential (WOCBP): negative serum pregnancy test during the Screening period and a negative urine pregnancy test up to 24 hours in advance of C1D1;
- WOCBP and males whose partners are WOCBP must agree to use a highly effective method of birth control throughout their participation and for 5 months following the last study drug administration.
Exclusion Criteria:
- Concurrent anticancer treatment, either FDA approved or investigational, for the cancer being evaluated in this study or for prior malignancies. A past history of other malignancies is allowed as long as the subject is not receiving treatment other than hormonal therapy and, in the judgment of the Investigator, is unlikely to have a recurrence. Of note, concurrent malignancies that do not require treatment and are clinically stable are allowed;
- Prior infusion of JTX-8064, LILRB2, or ILT4-directed therapy;
The therapies listed below within the specified timeframe or ongoing toxicity attributed to prior therapy that was >Grade 1 according to the NCI CTCAE, version 5.0. Exceptions: >Grade 1 toxicities that, in the opinion of the Investigator, should not exclude the subject (e.g., alopecia, Grade 2 neuropathy, hypo- or hyperthyroidism, or other endocrinopathies that are well controlled with hormone replacement) and are approved by the Medical Monitor:
- Major surgery (excluding minor procedures, for example, placement of vascular access, gastrointestinal/biliary stent, biopsy) <4 weeks prior to planned C1D1;
- Immunotherapy or biologic therapy <28 days prior to planned C1D1 or 5 half-lives, whichever is shorter;
- Chemotherapy <21 days prior to planned C1D1, or <42 days for mitomycin or nitrosoureas or 5 half-lives, whichever is shorter;
- Targeted small molecule therapy <14 days or 5 half-lives, whichever is shorter, prior to planned C1D1;
- Hormonal or other adjunctive therapy for cancers other than the cancer under evaluation in this study that started <14 days prior to planned C1D1 are not permitted; however, antiestrogen therapy, bisphosphonates, somatostatin analogues, leuprolide, and denosumab are permitted if started ≥14 days prior to C1D1. Other hormonal treatments and/or treatment for stable cancers (other than the cancer being treated on-study) may also be permitted 1) if these therapies would not be expected to have any positive or negative effect on the cancer being treated and 2) if discussed with and approved by the Medical Monitor;
- Radiation therapy <21 days prior to planned C1D1. Exception: Limited (e.g., pain palliation) radiation therapy is allowed prior to and during study drug administration as long as there are no acute toxicities, any AE due to prior radiation therapy has recovered to <Grade 2, and the radiation is not administered to a target lesion;
- Any prior organ transplantation, including allogeneic or autologous stem cell transplantation;
- History of intolerance, hypersensitivity, or treatment discontinuation due to Grade 3 or greater irAEs (related to prior immunotherapy);
- Diagnosis of immunodeficiency, either primary or acquired, or treatment with immunosuppressive levels of systemic corticosteroids (equivalent to ≥10 mg prednisone per day) or any other form of immunosuppressive therapy within 7 days prior to planned C1D1. Exception: Inhaled, intra-articular, topical, or systemic corticosteroids (systemic only at doses intended for adrenal replacement) and doses of immunosuppressive agents used prophylactically for contrast allergies are permitted in the absence of active autoimmune disease;
- Known severe intolerance or life-threatening hypersensitivity reactions to humanized mAbs or IV immunoglobulin preparations; any history of anaphylaxis; known allergy to any of the study medications, their analogues, or excipients (sodium acetate, sucrose, sodium chloride and polysorbate 80) in the various formulations of any agent;
- Symptomatic or uncontrolled brain metastases, leptomeningeal disease, or spinal cord compression not definitively treated with surgery or radiation (brain metastases that are stable and asymptomatic after prior treatment will be allowed);
- Active and clinically relevant bacterial, fungal, or viral infection, including known hepatitis A, B, or C, or HIV (testing not required);
- Women who are pregnant or breastfeeding or who plan to become pregnant/breastfeed while on study; men who plan to father children during the study;
- History of pneumonitis requiring treatment with corticosteroids, interstitial lung disease, or severe (≥Grade 3) radiation pneumonitis (excluding localized radiation pneumonitis);
- History in the last 3 months of acute diverticulitis, intra-abdominal abscess, or gastrointestinal obstruction, unless approved by Medical Monitor;
- Symptomatic cardiac or cerebrovascular disease that is unresponsive to surgical or medical management;
- Medical or social condition that, in the opinion of the Investigator, might place the subject at increased risk, adversely affect compliance, or confound safety or other clinical study data interpretation;
- Active disease requiring systemic immunosuppressive therapy;
- Live vaccines ≤30 days of C1D1;
- Deep vein thrombosis, pulmonary embolism (including asymptomatic pulmonary embolism identified on imaging), or other thromboembolic event within the 6 months preceding C1D1 for JTX-8064 monotherapy cohorts only.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Stage 1, Dose Escalation: JTX-8064 monotherapy dose escalation
Dose Escalation, Stage 1: JTX-8064 Monotherapy.
Cohorts will enroll subjects with histologically or cytologically confirmed advanced/metastatic extracranial solid tumor malignancies.
|
Specified dose on specified days
Other Names:
|
Experimental: Stage 2, Dose Escalation: JTX-8064 in combination with pimivalimab
Dose Escalation, Stage 2: JTX-8064 in combination with pimivalimab.
Cohorts will enroll subjects with histologically or cytologically confirmed advanced/metastatic extracranial solid tumor malignancies.
|
Specified dose on specified days
Other Names:
Specified dose on specified days
Other Names:
|
Experimental: Stage 3 Expansion: JTX-8064 monotherapy (Ovarian)
Cohort will enroll subjects with advanced/metastatic PD-1/PD-L1 (PD-(L)1)-naïve, platinum-resistant ovarian cancer.
|
Specified dose on specified days
Other Names:
|
Experimental: Stage 4, Expansion: JTX-8064 in combination with pimivalimab (ccRCC)
JTX-8064 in combination with pimivalimab.
Cohort will enroll subjects with advanced/metastatic PD-(L)1i-experienced clear cell renal cell carcinoma (ccRCC).
|
Specified dose on specified days
Other Names:
Specified dose on specified days
Other Names:
|
Experimental: Stage 4, Expansion: JTX-8064 in combination with pimivalimab (TNBC)
JTX-8064 in combination with pimivalimab.
Cohort will enroll subjects with advanced/metastatic PD-(L)1i-experienced triple negative breast cancer (TNBC).
|
Specified dose on specified days
Other Names:
Specified dose on specified days
Other Names:
|
Experimental: Stage 4, Expansion: JTX-8064 in combination with pimivalimab (HNSCC)
JTX-8064 in combination with pimivalimab.
Cohort will enroll subjects with advanced/metastatic PD-(L)1-naïve, PD-L1+ head and neck squamous cell carcinoma (HNSCC).
|
Specified dose on specified days
Other Names:
Specified dose on specified days
Other Names:
|
Experimental: Stage 4, Expansion: JTX-8064 in combination with pimivalimab (Ovarian)
JTX-8064 in combination with pimivalimab.
Cohort will enroll subjects with advanced/metastatic PD-(L)1-naïve, platinum-resistant ovarian cancer.
|
Specified dose on specified days
Other Names:
Specified dose on specified days
Other Names:
|
Experimental: Stage 4, Expansion: JTX-8064 in combination with pimivalimab (NSCLC)
JTX-8064 in combination with pimivalimab.
Cohort will enroll subjects with advanced/metastatic PD-(L)1-experienced non-small cell lung cancer (NSCLC).
|
Specified dose on specified days
Other Names:
Specified dose on specified days
Other Names:
|
Experimental: Stage 4, Expansion: JTX-8064 in combination with pimivalimab (cSCC)
JTX-8064 in combination with pimivalimab.
Cohort will enroll subjects with advanced/metastatic PD-(L)1-experienced cutaneous squamous cell carcinoma (cSCC).
|
Specified dose on specified days
Other Names:
Specified dose on specified days
Other Names:
|
Experimental: Stage 4, Expansion: JTX-8064 in combination with pimivalimab (UPS & LPS)
JTX-8064 in combination with pimivalimab.
Cohort will enroll subjects with advanced/metastatic PD-(L)1-naïve undifferentiated pleomorphic sarcoma (UPS) and liposarcoma (LPS).
|
Specified dose on specified days
Other Names:
Specified dose on specified days
Other Names:
|
Experimental: Stage 4, Expansion: JTX-8064 in combination with pimivalimab (PD-(L)1i-experienced HNSCC)
JTX-8064 in combination with pimivalimab.
Cohort will enroll subjects with PD-(L)1i-experienced HNSCC.
|
Specified dose on specified days
Other Names:
Specified dose on specified days
Other Names:
|
Experimental: Stage 4, Expansion: JTX-8064 in combination with pimivalimab (BTC)
JTX-8064 in combination with pimivalimab.
Cohort will enroll subjects with biliary tract cancer (BTC), including intra-and extra-hepatic biliary duct cancer and cancer of the gallbladder.
All subjects must have progressed on or after gemcitabine/cisplatin (Gem/Cis) in the metastatic setting, must have PD-(L)1i resistance.
|
Specified dose on specified days
Other Names:
Specified dose on specified days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence and severity of DLTs, treatment-emergent adverse events (TEAEs), serious TEAEs, and discontinuation due to adverse events (AEs) evaluated using National Cancer Institute (NCI) Common Technology Criteria for Adverse Events (CTCAE) version 5.0
Time Frame: up to 24 months
|
up to 24 months
|
Determination of a RP2D for JTX-8064 monotherapy and in combination with a PD-1i
Time Frame: up to 24 months
|
up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cmax for PD-1i in combination with JTX-8064
Time Frame: Cycles 1 through 12 (each cycle is 21 days)
|
Cycles 1 through 12 (each cycle is 21 days)
|
Tmax for PD-1i in combination with JTX-8064
Time Frame: Cycles 1 through 12 (each cycle is 21 days)
|
Cycles 1 through 12 (each cycle is 21 days)
|
Cmin for PD-1i in combination with JTX-8064
Time Frame: Cycles 1 through 12 (each cycle is 21 days)
|
Cycles 1 through 12 (each cycle is 21 days)
|
For Stages 3 and 4: Preliminary efficacy endpoints: Percentage of subjects with tumor reduction at any time
Time Frame: up to 36 months
|
up to 36 months
|
Cmax (the maximum observed concentration) for JTX-8064 monotherapy and in combination with a PD-1i
Time Frame: Cycles 1 through 12 (each cycle is 21 days)
|
Cycles 1 through 12 (each cycle is 21 days)
|
Tmax (time of maximum observed concentration) for JTX-8064 monotherapy and in combination with a PD-1i
Time Frame: Cycles 1 through 12 (each cycle is 21 days)
|
Cycles 1 through 12 (each cycle is 21 days)
|
Cmin for JTX-8064 monotherapy and in combination with a PD-1i
Time Frame: Cycles 1 through 12 (each cycle is 21 days)
|
Cycles 1 through 12 (each cycle is 21 days)
|
AUClast (area under the concentration-time curve from time 0 to the last measurable concentration) for JTX-8064 monotherapy and in combination with a PD-1i
Time Frame: Cycles 1 and 3 (each cycle is 21 days)
|
Cycles 1 and 3 (each cycle is 21 days)
|
Incidence of anti-drug antibodies (ADAs) to JTX-8064 and, as appropriate, to PD-1i
Time Frame: Baseline through Cycle 12 (each cycle is 21 days)
|
Baseline through Cycle 12 (each cycle is 21 days)
|
Incidence of neutralizing antibodies (Nabs) to JTX-8064 and, as appropriate, to PD-1i
Time Frame: Baseline through Cycle 12 (each cycle is 21 days)
|
Baseline through Cycle 12 (each cycle is 21 days)
|
For Stages 1 and 2: Receptor occupancy for LILRB2 on monocytes in whole blood
Time Frame: Baseline through Cycle 6 (each cycle is 21 days)
|
Baseline through Cycle 6 (each cycle is 21 days)
|
For Stages 3 and 4: Preliminary efficacy endpoints: Objective response rate (ORR; the proportion of subjects who have had a partial response [PR] or complete response [CR]) as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Time Frame: up to 36 months
|
up to 36 months
|
For Stages 3 and 4: Preliminary efficacy endpoints: Disease control rate (DCR; the proportion of subjects who have a PR, CR, or stable disease [SD]), as per RECIST version 1.1
Time Frame: up to 36 months
|
up to 36 months
|
For Stages 3 and 4: Preliminary efficacy endpoints: Progression-free survival (PFS; the interval from start of treatment to the earlier of first documentation of disease progression or death from any cause)
Time Frame: up to 36 months
|
up to 36 months
|
For Stages 3 and 4: Preliminary efficacy endpoints: Overall survival (OS; the interval from start of treatment to death of any cause)
Time Frame: up to 36 months
|
up to 36 months
|
For Stages 3 and 4: Preliminary efficacy endpoints: Duration of response (DOR; the time from documentation of tumor progression or death due to any cause, whichever comes first)
Time Frame: up to 36 months
|
up to 36 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Stew Kroll, Jounce Therapeutics, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- JTX-8064-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Palleon Pharmaceuticals, Inc.RecruitingMelanoma | Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | NSCLC | Non Small Cell Lung Cancer | Bladder Cancer | Colon Cancer | Urothelial Cancer | Oncology | CRC | Esophagogastric Junction Cancer | EGJUnited States
Clinical Trials on JTX-8064
-
Jounce Therapeutics, Inc.Active, not recruitingNSCLCTurkey, Latvia, Serbia, Ukraine, Russian Federation, Romania, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Georgia, Hungary, Moldova, Republic of, Slovakia
-
Jounce Therapeutics, Inc.Completed
-
Jounce Therapeutics, Inc.Completed
-
Jounce Therapeutics, Inc.Completed
-
Jounce Therapeutics, Inc.Completed